Aclaris Therapeutics Capital Expenditures (CapEx) Growth & History (ACRS)
Aclaris Therapeutics's capital expenditures (capex) was $111,000 for fiscal 2025.
View full Aclaris Therapeutics company overviewAclaris Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $111,000 | −$10,000 | −8.26% |
| 2024 | 2024-12-31 | $121,000 | −$1.2M | −90.76% |
| 2023 | 2023-12-31 | $1.3M | $704,000 | +116.36% |
| 2022 | 2022-12-31 | $605,000 | $297,000 | +96.43% |
| 2021 | 2021-12-31 | $308,000 | −$145,000 | −32.01% |
| 2020 | 2020-12-31 | $453,000 | −$1.2M | −71.92% |
| 2019 | 2019-12-31 | $1.6M | $257,000 | +18.95% |
| 2018 | 2018-12-31 | $1.4M | $121,000 | +9.80% |
| 2017 | 2017-12-31 | $1.2M | $1.0M | +432.33% |
| 2016 | 2016-12-31 | $232,000 | −$275,000 | −54.24% |
| 2015 | 2015-12-31 | $507,000 | $90,000 | +21.58% |
| 2014 | 2014-12-31 | $417,000 | — | — |
Aclaris Therapeutics quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $58,000 | $37,000 | +176.19% |
| Q1 2026 | 2026-03-31 | $13,000 | −$30,000 | −69.77% |
| Q4 2025 | 2025-12-31 | $24,000 | $24,000 | — |
| Q3 2025 | 2025-09-30 | $23,000 | $23,000 | — |
| Q2 2025 | 2025-06-30 | $21,000 | $7,000 | +50.00% |
| Q1 2025 | 2025-03-31 | $43,000 | −$92,000 | −68.15% |
| Q4 2024 | 2024-12-31 | $0 | −$441,000 | — |
| Q3 2024 | 2024-09-30 | $0 | −$84,000 | — |
| Q2 2024 | 2024-06-30 | $14,000 | −$217,000 | −93.94% |
| Q1 2024 | 2024-03-31 | $135,000 | −$418,000 | −75.59% |
| Q4 2023 | 2023-12-31 | $441,000 | $336,000 | +320.00% |
| Q3 2023 | 2023-09-30 | $84,000 | −$66,000 | −44.00% |
| Q2 2023 | 2023-06-30 | $231,000 | $45,000 | +24.19% |
| Q1 2023 | 2023-03-31 | $553,000 | $389,000 | +237.20% |
| Q4 2022 | 2022-12-31 | $105,000 | — | — |
| Q3 2022 | 2022-09-30 | $150,000 | $94,000 | +167.86% |
| Q2 2022 | 2022-06-30 | $186,000 | — | — |
| Q1 2022 | 2022-03-31 | $164,000 | — | — |
| Q3 2021 | 2021-09-30 | $56,000 | −$248,000 | −81.58% |
| Q4 2020 | 2020-12-31 | $8,000 | −$258,000 | −96.99% |
| Q3 2020 | 2020-09-30 | $304,000 | −$518,000 | −63.02% |
| Q2 2020 | 2020-06-30 | $17,000 | −$224,000 | −92.95% |
| Q1 2020 | 2020-03-31 | $124,000 | −$160,000 | −56.34% |
| Q4 2019 | 2019-12-31 | $266,000 | $120,000 | +82.19% |
| Q3 2019 | 2019-09-30 | $822,000 | $262,000 | +46.79% |
| Q2 2019 | 2019-06-30 | $241,000 | −$111,000 | −31.53% |
| Q1 2019 | 2019-03-31 | $284,000 | −$14,000 | −4.70% |
| Q4 2018 | 2018-12-31 | $146,000 | −$431,000 | −74.70% |
| Q3 2018 | 2018-09-30 | $560,000 | $290,000 | +107.41% |
| Q2 2018 | 2018-06-30 | $352,000 | $159,000 | +82.38% |
| Q1 2018 | 2018-03-31 | $298,000 | $103,000 | +52.82% |
| Q4 2017 | 2017-12-31 | $577,000 | $515,000 | +830.65% |
| Q3 2017 | 2017-09-30 | $270,000 | $206,000 | +321.88% |
| Q2 2017 | 2017-06-30 | $193,000 | $127,000 | +192.42% |
| Q1 2017 | 2017-03-31 | $195,000 | $155,000 | +387.50% |
| Q4 2016 | 2016-12-31 | $62,000 | −$70,000 | −53.03% |
| Q3 2016 | 2016-09-30 | $64,000 | −$69,000 | −51.88% |
| Q2 2016 | 2016-06-30 | $66,000 | −$99,000 | −60.00% |
| Q1 2016 | 2016-03-31 | $40,000 | −$37,000 | −48.05% |
| Q4 2015 | 2015-12-31 | $132,000 | — | — |
| Q3 2015 | 2015-09-30 | $133,000 | — | — |
| Q2 2015 | 2015-06-30 | $165,000 | — | — |
| Q1 2015 | 2015-03-31 | $77,000 | — | — |
Aclaris Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Aclaris Therapeutics's capital expenditures (capex) decreased from $453,000 to $111,000, a change of −$342,000. The latest reported quarter, Q2 2026, shows $58,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aclaris Therapeutics source filings ↗